Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Current Deferred Revenue (2016 - 2025)

Iradimed (IRMD) has disclosed Current Deferred Revenue for 13 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 27.04% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 27.04% year-over-year, with the annual reading at $2.9 million for FY2025, 27.04% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $2.9 million at Iradimed, down from $3.2 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $3.4 million in Q4 2022, with the low at $1.6 million in Q3 2022.
  • Average Current Deferred Revenue over 5 years is $2.5 million, with a median of $2.5 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue soared 58.74% in 2021, then tumbled 35.05% in 2022.
  • Over 5 years, Current Deferred Revenue stood at $2.6 million in 2021, then skyrocketed by 32.12% to $3.4 million in 2022, then dropped by 23.8% to $2.6 million in 2023, then decreased by 12.08% to $2.3 million in 2024, then increased by 27.04% to $2.9 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $2.9 million, $3.2 million, and $3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.